ViroGates AS (OCSE:VIRO) Piotroski F-Score: 5 (As of Jun. 27, 2026) — 25% Above Median


OCSE:VIRO ViroGates AS OCSE:VIRO
44 GF Score
Price kr10.60
GF Value kr6.80
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Piotroski F-Score?

ViroGates AS OCSE:VIRO +3.92% 44 Piotroski F-Score is 5 as of Jun. 27, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates OCSE:VIRO with a GF Score™ of 44/100 and a GF Value™ of kr6.80 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, ViroGates AS ranks better than 64.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ViroGates AS has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for ViroGates AS's Piotroski F-Score or its related term are showing as below:

OCSE:VIRO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 5
Current: 5

During the past 10 years, the highest Piotroski F-Score of ViroGates AS was 5. The lowest was 1. And the median was 4.

ViroGates AS  (OCSE:VIRO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ViroGates AS Piotroski F-Score Related Terms


ViroGates AS Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Piotroski F-Score Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 0.00 3.00 4.00

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 4.00 4.00 5.00

OCSE:VIRO vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, ViroGates AS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates AS Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ViroGates AS's Piotroski F-Score falls into.


OCSE:VIRO
44GF Score
ViroGates AS OCSE:VIRO
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -3.247 + -1.93 + -2.436 + -2.611 = kr-10.22 Mil.
Cash Flow from Operations was 0.907 + -2.492 + -1.558 + -3.735 = kr-6.88 Mil.
Revenue was 3.666 + 1.673 + 2.363 + 1.303 = kr9.01 Mil.
Gross Profit was 3.082 + 1.059 + 1.948 + 0.976 = kr7.07 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(16.02 + 17.985 + 14.21 + 30.589 + 26.771) / 5 = kr21.115 Mil.
Total Assets at the begining of this year (Mar25) was kr16.02 Mil.
Long-Term Debt & Capital Lease Obligation was kr3.02 Mil.
Total Current Assets was kr26.59 Mil.
Total Current Liabilities was kr6.96 Mil.
Net Income was -4.094 + -2.228 + -4.427 + -2.784 = kr-13.53 Mil.

Revenue was 1.078 + 3 + 1.568 + 1.202 = kr6.85 Mil.
Gross Profit was 0.455 + 2.409 + 0.78 + 0.532 = kr4.18 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(20.177 + 15.961 + 14.061 + 17.66 + 16.02) / 5 = kr16.7758 Mil.
Total Assets at the begining of last year (Mar24) was kr20.18 Mil.
Long-Term Debt & Capital Lease Obligation was kr4.27 Mil.
Total Current Assets was kr15.84 Mil.
Total Current Liabilities was kr3.74 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ViroGates AS's current Net Income (TTM) was -10.22. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ViroGates AS's current Cash Flow from Operations (TTM) was -6.88. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-10.224/16.02
=-0.63820225

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-13.533/20.177
=-0.67071418

ViroGates AS's return on assets of this year was -0.63820225. ViroGates AS's return on assets of last year was -0.67071418. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ViroGates AS's current Net Income (TTM) was -10.22. ViroGates AS's current Cash Flow from Operations (TTM) was -6.88. ==> -6.88 > -10.22 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=3.017/21.115
=0.14288421

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=4.273/16.7758
=0.25471214

ViroGates AS's gearing of this year was 0.14288421. ViroGates AS's gearing of last year was 0.25471214. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=26.585/6.962
=3.81858661

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=15.839/3.736
=4.23956103

ViroGates AS's current ratio of this year was 3.81858661. ViroGates AS's current ratio of last year was 4.23956103. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ViroGates AS's number of shares in issue this year was 9.282. ViroGates AS's number of shares in issue last year was 7.734. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=7.065/9.005
=0.78456413

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.176/6.848
=0.60981308

ViroGates AS's gross margin of this year was 0.78456413. ViroGates AS's gross margin of last year was 0.60981308. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=9.005/16.02
=0.56210986

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=6.848/20.177
=0.33939634

ViroGates AS's asset turnover of this year was 0.56210986. ViroGates AS's asset turnover of last year was 0.33939634. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ViroGates AS has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
ViroGates AS (OCSE:VIRO) has a Piotroski F-Score of 5 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ViroGates AS and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, ViroGates AS's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, ViroGates AS ranks #282 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is ViroGates AS's Piotroski F-Score too high?
ViroGates AS's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. ViroGates AS's value of 5 is 0% at this industry median. Based on the distribution chart, ViroGates AS ranks #282 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ViroGates AS has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #282 out of 805 companies for Piotroski F-Score. This puts ViroGates AS in the upper half of its industry. The industry median Piotroski F-Score is 5.00. ViroGates AS's value of 5 is 0% at this benchmark. Historically, ViroGates AS's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, ViroGates AS has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.80, compared to a current price of kr10.60 — trading 55.9% above its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 0% at the Medical Devices & Instruments industry median of 5.00. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Piotroski F-Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr10.60 is trading 55.9% above its estimated GF Value™ of kr6.80. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
  • GF Value™: kr6.80 vs. price of kr10.60 (55.9% above fair value)
  • GF Score™: 44/100 with 2 warning signs
  • Industry Position: 0% at the Medical Devices & Instruments median (#282 of 805)

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for OCSE:VIRO

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.60
Price
kr6.80
GF Value